Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7–Blocking Therapy in Inflammatory Bowel Disease
Veronika Horn , Camila A. Cancino , Lisa M. Steinheuer , Benedikt Obermayer , Konstantin Fritz , Anke L. Nguyen , Kim Susan Juhran , Christina Plattner , Diana Bösel , Lotte Oldenburg , Marie Burns , Axel Ronald Schulz , Mariia Saliutina , Eleni Mantzivi , Donata Lissner , Thomas Conrad , Mir-Farzin Mashreghi , Sebastian Zundler , Elena Sonnenberg , Michael Schumann , Ahmed N. Hegazy
{"title":"Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7–Blocking Therapy in Inflammatory Bowel Disease","authors":"Veronika Horn , Camila A. Cancino , Lisa M. Steinheuer , Benedikt Obermayer , Konstantin Fritz , Anke L. Nguyen , Kim Susan Juhran , Christina Plattner , Diana Bösel , Lotte Oldenburg , Marie Burns , Axel Ronald Schulz , Mariia Saliutina , Eleni Mantzivi , Donata Lissner , Thomas Conrad , Mir-Farzin Mashreghi , Sebastian Zundler , Elena Sonnenberg , Michael Schumann , Ahmed N. Hegazy","doi":"10.1053/j.gastro.2024.09.021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & Aims</h3><div>Despite the success of biological therapies in treating inflammatory bowel disease, managing patients remains challenging due to the absence of reliable predictors of therapy response.</div></div><div><h3>Methods</h3><div>In this study, we prospectively sampled 2 cohorts of patients with inflammatory bowel disease receiving the anti-integrin α4β7 antibody vedolizumab. Samples were subjected to mass cytometry; single-cell RNA sequencing; single-cell B and T cell receptor sequencing (BCR/TCR-seq); serum proteomics; and multiparametric flow cytometry to comprehensively assess vedolizumab-induced immunologic changes in the peripheral blood and their potential associations with treatment response.</div></div><div><h3>Results</h3><div>Vedolizumab treatment led to substantial alterations in the abundance of circulating immune cell lineages and modified the T-cell receptor diversity of gut-homing CD4<sup>+</sup> memory T cells. Through integration of multimodal parameters and machine learning, we identified a significant increase in proliferating CD4<sup>+</sup> memory T cells among nonresponders before treatment compared with responders. This predictive T-cell signature demonstrated an activated T-helper 1/T-helper 17 cell phenotype and exhibited elevated levels of integrin α4β1, potentially making these cells less susceptible to direct targeting by vedolizumab.</div></div><div><h3>Conclusions</h3><div>These findings provide a reliable predictive classifier with significant implications for personalized inflammatory bowel disease management.</div></div>","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"168 2","pages":"Pages 327-343"},"PeriodicalIF":25.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0016508524055276","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background & Aims
Despite the success of biological therapies in treating inflammatory bowel disease, managing patients remains challenging due to the absence of reliable predictors of therapy response.
Methods
In this study, we prospectively sampled 2 cohorts of patients with inflammatory bowel disease receiving the anti-integrin α4β7 antibody vedolizumab. Samples were subjected to mass cytometry; single-cell RNA sequencing; single-cell B and T cell receptor sequencing (BCR/TCR-seq); serum proteomics; and multiparametric flow cytometry to comprehensively assess vedolizumab-induced immunologic changes in the peripheral blood and their potential associations with treatment response.
Results
Vedolizumab treatment led to substantial alterations in the abundance of circulating immune cell lineages and modified the T-cell receptor diversity of gut-homing CD4+ memory T cells. Through integration of multimodal parameters and machine learning, we identified a significant increase in proliferating CD4+ memory T cells among nonresponders before treatment compared with responders. This predictive T-cell signature demonstrated an activated T-helper 1/T-helper 17 cell phenotype and exhibited elevated levels of integrin α4β1, potentially making these cells less susceptible to direct targeting by vedolizumab.
Conclusions
These findings provide a reliable predictive classifier with significant implications for personalized inflammatory bowel disease management.
期刊介绍:
Gastroenterology is the most prominent journal in the field of gastrointestinal disease. It is the flagship journal of the American Gastroenterological Association and delivers authoritative coverage of clinical, translational, and basic studies of all aspects of the digestive system, including the liver and pancreas, as well as nutrition.
Some regular features of Gastroenterology include original research studies by leading authorities, comprehensive reviews and perspectives on important topics in adult and pediatric gastroenterology and hepatology. The journal also includes features such as editorials, correspondence, and commentaries, as well as special sections like "Mentoring, Education and Training Corner," "Diversity, Equity and Inclusion in GI," "Gastro Digest," "Gastro Curbside Consult," and "Gastro Grand Rounds."
Gastroenterology also provides digital media materials such as videos and "GI Rapid Reel" animations. It is abstracted and indexed in various databases including Scopus, Biological Abstracts, Current Contents, Embase, Nutrition Abstracts, Chemical Abstracts, Current Awareness in Biological Sciences, PubMed/Medline, and the Science Citation Index.